Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • ‘Close to thin ice’: looming credit crunch puts pressure on Fed
    • Rahul Gandhi sentenced to two years in prison over Modi remarks
    • Spanish leader to discuss Ukraine war on Xi visit
    • Federal Reserve presses ahead with quarter-point rate rise despite banking turmoil
    • China’s billionaires pay the price for Xi Jinping’s Covid crackdown
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Swiss regulator defends $17bn wipeout of AT1 bonds in Credit Suisse deal
      • Accenture to axe 19,000 jobs
      • Hindenburg Research shorts Jack Dorsey’s payments group Block
      • EY’s US boss warns it is ‘premature’ to say whether break-up plan can be salvaged
      • Credit funds scrutinise ‘mythical, enormous’ Silicon Valley Bank loan book
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Swiss regulator defends $17bn wipeout of AT1 bonds in Credit Suisse deal
      • News updates from March 23: Hindenburg launches attack on Jack Dorsey’s payments group Block, BoE raises rates
      • Hindenburg Research shorts Jack Dorsey’s payments group Block
      • US charges crypto fugitive Do Kwon after Montenegro arrest
      • Commercial property risks rise up bank investors’ worry list
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • Beware the ‘sensible’ crypto crowd — they’re worse than the fanatics
      • Credit Suisse’s fate casts a shadow over the European banking sector
      • Risk of ‘industrial capture’ looms over AI revolution
      • How European entrepreneurs can live the American dream
      • A hefty shock awaits those who see little difference between Starmer and Sunak
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Culture clash: the challenge of uniting fierce rivals UBS and Credit Suisse
      • From SVB to the BBC: why did no one see the crisis coming?
      • Social media content moderators lead charge for better rights
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Everything I, an Italian, thought I knew about Italian food is wrong
      • We should regulate SUVs out of existence
      • Is France on the road to a Sixth Republic?
      • Credit Suisse ‘merch’ and the rush to buy history
      • Hot property: five homes for sale in the Lake District
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Hannah Kuchler

    Global Pharmaceuticals Correspondent

    Hannah Kuchler reports on the pharmaceutical industry and the Covid-19 pandemic. She previously covered US pharma and biotech in New York and the technology industry in Silicon Valley.
    Email Hannah Kuchler @hannahkuchler  on Twitter (link opens in a new browser window)

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Wednesday, 22 March, 2023
      Drugs research
      Novartis scraps drug trial in blow to UK life sciences ambitions

      Swiss group rethinks NHS collaboration after low take-up of treatment during rollout via GPs

    • Tuesday, 21 March, 2023
      Oxford Nanopore Technologies
      Oxford Nanopore open to possibility of overseas listing

      UK genomic sequencing group ‘not ruling out’ any options, says chief executive

    • Sunday, 19 March, 2023
      UK politics & policy
      Medicines regulator seeks to shake off UK ‘isolationist’ label with new alliance

      MHRA chief in talks with watchdogs in Australia, Canada, Singapore and Switzerland to create partnership

    • Thursday, 16 March, 2023
      Novo Nordisk AS
      Novo Nordisk suspended from UK industry group after rule violation

      Regulators find Danish drugmaker sponsored ‘disguised’ promotional campaign

    • Wednesday, 15 March, 2023
      UK Budget
      Hunt’s R&D shake-up divides small businesses

      Life sciences and AI groups welcome UK government’s rethink on tax credits, but less cutting-edge start-ups face funding drop

    • Wednesday, 15 March, 2023
      UK Budget
      Computing and life sciences to benefit from UK financial and regulatory measures

      Chancellor Jeremy Hunt vows to make Britain the ‘best place in Europe’ for tech companies to invest

    • Monday, 13 March, 2023
      News in-depthSilicon Valley Bank
      Project Yeti: How HSBC bought Silicon Valley Bank UK for £1

      Prime Minister Rishi Sunak and Bank of England raced to orchestrate a sale

    • Monday, 13 March, 2023
      Pfizer Inc
      Pfizer to buy oncology-focused biotech Seagen for $43bn

      US pharma group to pay $229 a share in cash deal that signals rebound in M&A activity

    • Tuesday, 7 March, 2023
      Covid-19 vaccines
      UK spring Covid boosters will target elderly and vulnerable

      Health secretary confirms acceptance of advice from expert committee to ‘bridge the gap’ to autumn

    • Thursday, 2 March, 2023
      FT Magazine
      A controversial biotech and an unlikely anorexia treatment 

      A Nasdaq-listed company is trialling the active ingredient in magic mushrooms as a new treatment

    • Wednesday, 1 March, 2023
      Drug prices
      UK says drugmakers’ call for fixed-rate medicines tax ‘unaffordable’

      Health department says industry’s plan, published ahead of talks, would limit access to new medicines

    • Monday, 27 February, 2023
      News in-depthDrug prices
      Drugmakers demand big cut in Britain’s medicines levy

      UK pharma industry claims that de facto tax will hurt research and development investment

    • Sunday, 26 February, 2023
      Bayer AG
      Bayer embraces activist Ubben with place on its sustainability council

      But high-profile shareholder may not be satisfied with informal position

    • Tuesday, 21 February, 2023
      Healthcare
      Smith & Nephew warns chip shortages still affecting medical industry

      Regulatory restrictions hamper companies despite recovery in semiconductor supply, says chief

    • Monday, 20 February, 2023
      Special ReportImpact Investing
      Impact funds help fight dementia and antibiotic resistance

      Some of the world’s biggest health challenges do not lend themselves to conventional investment

    • Sunday, 12 February, 2023
      Pharmaceuticals sector
      Women’s health ‘missing out’ because of male-dominated investment

      Pharma chief says sector is seen as ‘niche’ and leaves women suffering from healthcare inequality

    • Sunday, 12 February, 2023
      Novo Nordisk AS
      Novo Nordisk apologises for not disclosing sponsorship of anti-obesity training

      Healthcare professionals encouraged to prescribe group’s weight loss drug as part of ‘disguised’ promotional campaign

    • Thursday, 9 February, 2023
      AstraZeneca PLC
      AstraZeneca chief says industry should not pay for NHS Covid costs

      Pascal Soriot criticises pricing agreement with UK health service

    • Sunday, 29 January, 2023
      Drugs research
      RQ Bio partners with AstraZeneca in Covid antibody fight

      UK biotech racing to keep antibody up to date with latest variants

    • Tuesday, 24 January, 2023
      News in-depthDrug prices
      Big pharma groups rejoin battle with governments on drug prices

      Tight budgets and US reforms are ending a truce between the industry and health authorities

    • Monday, 16 January, 2023
      Drug prices
      US drugmakers withdraw from NHS pricing agreement as costs soar

      AbbVie and Eli Lilly take action after clawback payments on branded drugs reach a quarter of UK sales

    • Monday, 16 January, 2023
      Bayer AG
      Bayer shifts pharma focus away from ‘innovation unfriendly’ Europe

      German group’s drugs chief warns EU and UK are dissuading investment as company prioritises US and China

    • Friday, 13 January, 2023
      UK politics & policy
      UK government admits R&D-heavy small companies need more tax help

      Business groups cautiously welcome acknowledgment that reform ‘creates challenges for some SMEs’

    • Friday, 13 January, 2023
      UK social care
      Private care homes push for sharp rise in prices to take on NHS patients

      Operators say higher tariff would allow them to attract and keep staff as hospitals look to free up space

    • Tuesday, 10 January, 2023
      Elliott Management Corp
      Elliott portfolio manager behind GSK and Fresenius campaigns leaves firm

      Sebastien de La Riviere’s move is latest in a number of high-profile departures inside activist’s London office

    Previous page You are on page 1 Next page

    Be part of FT Community

    Discover unmissable flagship events and members only communities to expand your thinking and elevate your career

    FT Live
    Health Technology Summit
    Transforming Life Sciences & Digitising Healthcare
    Thursday, 30th NovemberOnline
    Learn more about FT Community

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In